Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJessica R. Kirshner, Alison Crawford, Danica Chiu
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJessica R. Kirshner, Alison Crawford, Danica Chiu
Estimating the term…
Provided herein are methods of treating cancer using bispecific antigen-binding molecules that bind to prostate-specific membrane antigen (PSMA) and CD3. According to certain embodiments, the antibodies useful herein bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of prostate tumors expressing PSMA. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.
A method of treating a cancer or inhibiting the growth of a tumor comprising administering to a subject in need thereof a therapeutically effective amount of each of (a) an anti-CD3/anti-PSMA bispecific antigen-binding molecule;
A method of increasing expansion of CD8+ T cells in tumor tissue, the method comprising administering to a subject in need thereof a therapeutically effective amount of each of (a) an anti-CD3/anti-PSMA bispecific antigen-binding molecule;
A method of eliciting and/or enhancing a T cell response to a tumor, the method comprising administering to a subject in need thereof a therapeutically effective amount of each of (a) an anti-CD3/anti-PSMA bispecific antigen-binding molecule;
A pharmaceutical composition comprising:
A radiolabeled bispecific antibody conjugate comprising a bispecific antigen-binding molecule that binds PSMA and CD3, a chelating moiety, and a positron emitter.
Dependencies are inferred from the claim text.